Trial Profile

A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-015 in Patients With Advanced Malignant Tumors.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LBL-015 (Primary)
Indications Carcinoma; Colorectal cancer; Gastric cancer; Nasopharyngeal cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Leads Biolabs

28 Oct 2024 Status changed from recruiting to completed.
04 Jun 2024 Preliminary results (n=25; data cutoff date: 25 Dec 2023) reporting safety and efficacy data presented at the 60th Annual Meeting of the American Society of Clinical Oncology
13 May 2024 According to a Leads Biolabs media release, the company will present data from this study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting between May 31 to June 4, 2024 in Chicago.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com